CORRELATION BETWEEN THE EXPRESSION OF VEGF AND SURVIVAL IN OSTEOSARCOMA

Carregando...
Imagem de Miniatura
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
ATHA COMUNICACAO & EDITORA
Citação
ACTA ORTOPEDICA BRASILEIRA, v.22, n.5, p.250-255, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To present a series of 50 consecutive patients with non-metastatic extremity osteosarcoma, and attempt to correlate expression of the vascular endothelial growth factor (VEGF) protein in biopsy tissue to their prognosis regarding overall survival, disease-free survival and local recurrence. Methods: Fifty cases of non-metastatic osteosarcoma of the extremities treated between 1986 and 2006 at Instituto de Ortopedia e Traumatologia da Universidade de Sao Paulo, Sao Paulo, Brasil, were evaluated regarding expression of the VEGF protein. There were 19 females and 31 males. The mean age was 16 years old (range 5-28 years old) and the mean follow-up was 60.6 months (range 25-167 months). The variables studied were age, gender, anatomic location, type of surgery, surgical margins, tumor size, post chemotherapy necrosis, local recurrence, pulmonary metastasis and death. Results: Thirty-six patients showed VEGF expression on 30% or less cells (low), and the remaining 14 cases had VEGF expression above 30% (high). Among the 36 patients with low VEGF expression, nine developed pulmonary metastasis and four died (11.1%). Among the 14 patients with high VEGF expression, six developed pulmonary metastasis and three died (21.4%). Conclusion: There was no statistically significant correlation between the expression of VEGF and any of the variables studied.
Palavras-chave
Osteosarcoma, Prognosis, Neovascularization, pathologic
Referências
  1. Abdeen A, 2009, CANCER, V115, P5243, DOI 10.1002/cncr.24562
  2. Bajpai J, 2009, PEDIATR BLOOD CANCER, V53, P1035, DOI 10.1002/pbc.22178
  3. Becker RG, 2013, ACTA ORTOP BRAS, V21, P233, DOI 10.1590/S1413-78522013000400010
  4. Chen D, 2013, TUMOR BIOL, V34, P1895, DOI 10.1007/s13277-013-0733-z
  5. Ek Eugene T H, 2006, Int Semin Surg Oncol, V3, P7, DOI 10.1186/1477-7800-3-7
  6. Ek ETH, 2006, ONCOL REP, V16, P17
  7. Huang YP, 2008, ONKOLOGIE, V31, P535, DOI 10.1159/000151685
  8. Jung ST, 2005, ORTHOPEDICS, V28, P755
  9. Kaya M, 2000, CLIN CANCER RES, V6, P572
  10. Lammli J, 2012, INT ORTHOP, V36, P2307, DOI 10.1007/s00264-012-1629-z
  11. Lee YH, 1999, EUR J CANCER, V35, P1089, DOI 10.1016/S0959-8049(99)00073-8
  12. Lin F, 2011, MED ONCOL, V28, P649, DOI 10.1007/s12032-010-9493-4
  13. Lugowska I, 2011, PEDIATR BLOOD CANCER, V57, P63, DOI 10.1002/pbc.23021
  14. Marinho LC, 2009, THESIS U FEDERAL SAO
  15. Mizobuchi H, 2008, CLIN ORTHOP RELAT R, V466, P2052, DOI 10.1007/s11999-008-0328-y
  16. Oda Y, 2006, MODERN PATHOL, V19, P738, DOI 10.1038/modpathol.3800587
  17. Qu JT, 2012, J CANCER RES CLIN, V138, P819, DOI 10.1007/s00432-012-1149-7
  18. Rastogi S, 2012, INT ORTHOP, V36, P2315, DOI 10.1007/s00264-012-1663-x
  19. ROSEN G, 1976, CANCER, V37, P1, DOI 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3
  20. Rossi B, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-34
  21. Sulzbacher I, 2002, VIRCHOWS ARCH, V441, P345, DOI 10.1007/s00428-002-0671-4
  22. Yu XW, 2014, TUMOR BIOL, V35, P155, DOI 10.1007/s13277-013-1019-1
  23. Zhou QA, 2011, SURG ONCOL, V20, P13, DOI 10.1016/j.suronc.2009.09.002